Posted inGastroenterology news Oncology
Targeting Xanthine Oxidoreductase: A New Frontier to Overcome EGFR TKI Resistance in Intrahepatic Cholangiocarcinoma
Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progression.